Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory autoimmune disease affecting the skin; discoid lupus erythematosus (DLE) is the most prevalent subtype of CLE. To date, no FDA-approved treatments are available for the treatment of CLE / DLE. The current treatment landscape involves off-label prescribing of calcineurin inhibitors, antimalarials, immunosuppressants, corticosteroids, and sometimes other drug classes, including biologics (e.g., rituximab, ustekinumab). The CLE pipeline holds an array of therapies with unique mechanisms of action, such as an anti-BDCA2 monoclonal antibody (Biogen’s BIIB059), JAK inhibitors (LEO Pharma’s delgocitinib and Gilead / Galapagos’ filgotinib), and a Syk kinase inhibitor (Gilead / Galapagos’ lanraplenib). If proven efficacious, these agents will enjoy a substantial commercial opportunity because of the high unmet need in this space.
United States Primary Research 3 KOL interviews in January 2020
Key COMPANIES Covered
Biogen, LEO Pharma, Gilead, Galapagos
Key Drugs Covered
Hydroxychloroquine, mycophenolate mofetil, Revlimid, BIIB059, delgocitinib, filgotinib, lanraplenib
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.